PubMed Health⌕ Search

Biomedical subjects

D G Szabo

Publications and source records attributed to D G Szabo.

13 recordsLinked to original sources
PubMed1994

Immunohistochemical localization of pregnancy-related placental protein 4 in nontumorous tissues and in gynecological tumors.

The aim of the study was to demonstrate the localization of placental protein 4 (PP4) in different nontumorous and tumorous tissues originating from the female genital tract. PP4 immunoreactivity was demonstrated using the peroxidase-antiperoxidase immunohistochemical technique. Tissue samples were obtained from the cervix and body of the uterus, ovary, vulva and from gestational trophoblastic tumors. PP4-positive cells were present in nontumorous tissues with various pathologic findings, and in many but not all benign gynecological tumors. Similar numbers of PP4-positive cells were located in malignant and benign gynecological tumors; however, PP4 staining intensity was greater in the malignant lesions. PP4-positive cells were found in hydatidiform moles and in choriocarcinoma. PP4 was distributed mainly in the cytoplasm, but it was also bound to the cell membrane. We conclude from these studies that PP4 is located in a variety of benign and malignant cells of the female genital tract and that these cells may be the source of plasma PP4 found in patients with these conditions.

Female↗
PubMed1990

Circulating levels of placental protein 12 (PP 12) in diabetic pregnancy complicated by retinopathy.

Placental protein 12 (PP 12) is a soluble tissue antigen. Immunohistochemical studies have localized PP 12 in the placental syncytiotrophoblast, chorion and amnion, and also in the decidua. During normal pregnancy serum-PP 12 is already raised in the first trimester, there is then a peak at 18 weeks, a gradual fall until 32 weeks, and a moderate increase thereafter. The mean of the healthy control group at 18 weeks of pregnancy was 122.9 +/- 47.5 micrograms/l. The mean of the diabetic group with retinopathy at the same time was 192.2 +/- 78.8 micrograms/l. There was no significant difference between background retinopathy and the proliferative form of diabetic retinopathy. At all times during pregnancy the median values of PP 12 in diabetic pregnancies were significantly (p less than 0.01) above the control values. Increased PP 12 levels in diabetic pregnancy complicated by retinopathy are probably caused by decidual, placental and amniotic leakages.

Adult↗
PubMed1990

Circulating levels of placental protein 10 (PP 10) in diabetic pregnancy complicated by retinopathy.

Placental protein 10 (PP 10) is a soluble tissue antigen of the placenta. PP 10, a glycoprotein, was tested in diabetic pregnancy complicated by retinopathy. A continuous increase in PP 10 serum levels until weeks 35-36 is followed by a fall thereafter up to term. The mean of the healthy control group between 32 and 39 weeks gestation was 22 +/- 10 micrograms/l. In diabetic pregnancies complicated by retinopathy there were measured 69 +/- 24 micrograms/l in benign form and 77 +/- 26 micrograms/l in proliferative form. Both of these values are significantly (p less than 0.05) above the control values. Increased PP 10 levels in diabetic pregnancy complicated by retinopathy are probably caused by placental and amniotic leakages.

Adolescent↗
PubMed1989

Placental protein 12 (PP 12), a decidual protein, in pregnancy complicated by diabetes with retinopathy.

Placental protein 12 (IGF-bp/PP 12) is a soluble tissue antigen produced in the decidua. PP 12 was measured in the 3rd trimester of diabetic pregnancy complicated by retinopathy. The mean values of the healthy control group between 28 and 34 and between 35 and 39 weeks gestation were 108 +/- 39 micrograms/l and 124 +/- 47 micrograms/l, respectively. The equivalent values in diabetic pregnancies complicated by retinopathy were 200 +/- 80 micrograms/l and 204 +/- 81 micrograms/l, respectively; both these PP 12 values were significantly (P less than 0.05) above the values in the control group. There was no significant difference between benign and proliferative retinopathy. The increased PP 12 levels in the presence of diabetic retinopathy are probably caused by decidual degeneration.

Adolescent↗
PubMed1989

[Placental protein 12 (PP 12)/insulin-like growth factor binding protein (IGF-bp) in pregnancy in metabolically healthy patients and diabetic patients with retinopathy].

The placental protein 12 (PP 12) was found to be identical with the insulin like growth-factor binding protein (IGF-bp). In present investigations serum samples of 420 healthy pregnant women between 7th and 40th weeks of gestation were proved regarding to their IGF-bp concentrations by means of a radioimmunoassay. For each pregnancy week means and standard deviations were estimated. IGF-bp serum concentrations continuously increased up to the 18th week (140 +/- 40 micrograms/l); followed by decreasing of the values up to the 30th week (102 +/- 44 micrograms/l) and then slightly increased up to term (121 +/- 46 micrograms/l). In addition the IGF-bp estimations were performed in maternal serum samples of 45 diabetic pregnant women complicated by retinopathia diabetica benigna as well as proliferativa; sum total 101 serum samples. In patients with benign retinopathy 82% (12/68) and in patients of proliferative retinopathy 85% (5/33) of the IGF-bp values were increased above the two times standard deviation.

Adult↗
PubMed1988

Clinical evidence of secretory IgA and Schwangerschaftsprotein 1 in pleural effusions of lung cancer patients.

Secretory immunoglobulin A, alpha 1-fetoprotein, orosomucoid and alpha 2-macroglobulin have been estimated in pleural effusions of 11 lung cancer patients. Secretory immunoglobulin could be detected in all cancer patients except one with a secondary embolism. Levels could be found between 0.19 and 0.73 g/l. No SIgA could be detected in a control group of 7 patients with pleural effusions of other origin.

Enzyme-Linked Immunosorbent Assay↗
PubMed1987

[Pregnancy protein-1 in the serum of patients with diseases of the breast].

Pregnancy-specific beta 1-glycoprotein (SP1) was assayed by enzyme immunoassay in serum from 32 patients with breast diseases (11 mastopathies, 6 benign tumors and 15 breast cancers). Healthy blood donors were used as control group. There were significant differences between the SP1-serum concentrations of patient group (mastopathies, benign tumors, breast cancer) and the control group (p less than 0.001). The SP1-values of the groups with mastopathies, benign tumors and breast cancer did not differ significantly. Elevated SP1-concentrations were found in 4 of 11 patients with mastopathy, in 3 of 6 patients with benign tumor and in 10 of 15 patients with breast cancer versus 1 of 24 blood donors. With the help of SP1 determination in serum of 5 breast cancer patients before operation and 6 months post operation we did not found a correlation with further clinical course.

Adenocarcinoma, Scirrhous↗
PubMed1986

[Levels of tumor markers (orosomucoid, pregnancy-associated alpha 2-glycoprotein, pregnancy protein-1, placental specific-tissue protein 10, placental specific-tissue protein 12, alpha 1-fetoprotein) in the serum of patients with bronchial carcinoma].

Concentration of orosomucoid, pregnancy associated alpha 2-glycoprotein (alpha 2-PAG), Schwangerschaftsprotein 1 (SP1), placental specific-tissue protein 10 (PP10), placental specific-tissue protein 12 (PP12), alpha 1-Fetoprotein (AFP) were estimated in serum samples of 83 patients with lung cancer of stages II-IV. The proteins were determined by means of the single radial immunodiffusion, the rocket immunoelectrophoresis, the radioimmunoassay and the enzymeimmunoassay. Orosomucoid, PP12 and AFP serum concentrations of the cancer group compared with those of the control group, were increased significantly. Orosomucoid (control group: means = 0.828 g/l; s = 0.301; tumour group: mean = 2.16 g/l; s = 0.862); PP12 (control group: mean = 54.08 micrograms/l; s = 61.70; tumour group: mean = 122.52 micrograms/l; s = 131.16); AFP (control group: mean = 3.05 micrograms/l; s = 3.76; Tumour group: means = 8.29 micrograms/l; s = 17.75). alpha 2-PAG was found only in 37 cases of the tumour group; SP1 in 22 cases. PP10 (control group: mean = 2.25 micrograms/l; s = 0.866; tumour group: mean = 2.503 micrograms/l, s = 1.508). On condition that 2 tested parameters at least were estimated in the pathological range the sensitivity amounted to 0.64 and the specificity to 0.92.

Aged↗
PubMed1975

Investigation of the serum level of pregnancy-associated alpha2-globulin during contraceptive treatment by means of radial immunodiffusion method.

The serum level of pregnancy-associated alpha2-globulin was studied in 70 healthy women taking three different types of oral contraceptives [40 Bisecurin: containing 1.0 mg of Ethynodiol diaceticum +0.05 mg Ethynilestradiol; 20 Infecundin: containing 2.5 mg of Norethynodrel +0.1 mg of Mestranol; 10 Cervicundin: containing of 0.5 mg Ethynodiol diaceticum]. Elevated amounts of serum level of pregnancy associated alpha2-globulin could be detected in 37 of the 40 women taking Bisecurin and in all 20 taking Infecundin. Cervicundin however, failed to induce any change in the serum protein pattern of the 10 subjects studied. Serum levels of pregnancy-associated alpha2-globulin were higher in the Infecundin-taking (53 mg %), than in the Bisecurin-taking group (29 mg %). This shows the oestrogen dependency of the pregnancy-associated alpha2-globulin and points to a possible implication of this globulin in the immunosuppressive processes.

Alpha-Globulins↗
PubMedDate not supplied

Tumor markers (pregnancy protein 1, placental-specific tissue protein 10, placental-specific tissue protein 12, alpha1-fetoprotein) in patients with bronchial carcinoma.

The concentrations of pregnancy protein 1 (SP1), placental-specific tissue protein 10 (PP10), placental-specific tissue protein 12 (PP12) and alpha1-Fetoprotein (AFP) were analyzed in serum samples of 83 patients with bronchial carcinoma at stages II-IV Protein levels were determined by means of single radial immunodiffusion, rocket immuno-electrophoresis, radioimmunoassay and enzyme- immunoassay. PP12 and AFP serum concentrations were significantly increased in the cancer group compared with the control group. PP12 (control group: x=54.08 microg/l; s=61. 70; tumor group: x = 122.52 microg/l; s = 131.16); AFP (control group: x=3.05 microg/l; s=3. 76; tumor group: x = 8.29 microg/l; s = 17.75). SPI was found in only 22 cases of the tumor group. PP10 (control group: x = 2.25 microg/l; s = 0.866; tumor group: x = 2.503 microg/l; s=1.508). Given that at least two of the tested parameters were determined to be in the pathological range, the sensitivity amounted to 0.64 and the specificity to 0.92.

Biomarkers, Tumor↗